Abiopharma

BANCO SANTANDER S.A. (SAN)

Symbol	SAN
Name	BANCO SANTANDER S.A.
Sector	FINANCE
Region	Europe
Industry	-
Address	s/n 28660 Spain Santander Group City Av. de Cantabria
Telephone	(+34) 91 259 65 20
Fax	—
Email	—
Website	http://www.santander.com
Incorporation	ES
Incorporated On	—
Employees	—
Fiscal Year	12/31
Public Since	—
Exchanges	OTC;NASDAQ
Auditor	—
Audit Status	AUDITED
Reporting Status	U.S. Reporting: SEC Reporting
CIK	0000891478
Description	Banco Santander Central Hispano is the parent company of a group engaged in commercial and investment banking, financial products and services, including services such as: credit cards; mergers and acquisitions; stock brokerage; mortgages; mutual fund management; factoring; and asset management. Additional info from NASDAQ: Banco Santander Rio SA is an Argentina-based financial institution (the Bank) principally engaged in the banking sector. The Banks offer includes current and saving accounts, mortgage, consumer and commercial loans, fixed-term deposits, credit and debit cards, financial advisory, wealth management, banking guarantees, cash management, export and project financing, mergers and acquisition (M&A) transactions, custody, leasing, as well as securities brokerage, among others. Its banking business in structured in four areas: Personal, Small and medium-sized enterprises (SMEs), Corporate and Wholesale. In addition, the Bank provides life and casualty insurance products. Additional info from OTC: Banco Santander Central Hispano is the parent company of a group engaged in commercial and investment banking, financial products and services, including services such as: credit cards; mergers and acquisitions; stock brokerage; mortgages; mutual fund management; factoring; and asset management.

2026-07-10 16:30

Sanofi: Information concerning the total number of voting rights and shares - June 2026

2026-07-10 16:30

Sanofi: Informations relatives au nombre de droits de vote et dactions - Juin 2026

2026-07-01 05:30

Press Release: Availability of the aide-mémoire for Q2 2026 results

2026-07-01 05:30

Communiqué de presse : Mise en ligne du document «Q2 2026 aide-mémoire »

2026-06-30 05:00

Communiqué de presse : Le Nexviazyme de Sanofi a atteint tous les critères d’évaluation principaux et secondaires dans une étude de phase III sur la forme infantile de la maladie de Pompe

2026-06-30 05:00

Press Release: Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study

2026-06-25 06:00

Press Release: Sanofi Foundation opens new chapter centered on future generations

2026-06-25 06:00

Communiqué de presse : La Fondation Sanofi ouvre un nouveau chapitre centré sur les générations futures

2026-06-23 05:15

Communiqué de presse : Wayrilz de Sanofi a été approuvé au Japon pour traiter la thrombocytopénie immunitaire

2026-06-23 05:15

Press Release: Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopenia